Certara/$CERT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Certara
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
Ticker
$CERT
Sector
Primary listing
Employees
1,517
Headquarters
Website
Certara Metrics
BasicAdvanced
$1.8B
232.00
$0.05
1.43
-
Price and volume
Market cap
$1.8B
Beta
1.43
52-week high
$15.69
52-week low
$8.64
Average daily volume
1.5M
Financial strength
Current ratio
2.157
Quick ratio
2.065
Long term debt to equity
28.314
Total debt to equity
28.998
Interest coverage (TTM)
1.63%
Profitability
EBITDA (TTM)
104.733
Gross margin (TTM)
61.14%
Net profit margin (TTM)
1.97%
Operating margin (TTM)
7.96%
Effective tax rate (TTM)
29.45%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
1.31%
Return on equity (TTM)
0.76%
Valuation
Price to earnings (TTM)
231.996
Price to revenue (TTM)
4.563
Price to book
1.73
Price to tangible book (TTM)
-10.81
Price to free cash flow (TTM)
23.9
Free cash flow yield (TTM)
4.18%
Free cash flow per share (TTM)
0.482
Growth
Revenue change (TTM)
11.61%
Earnings per share change (TTM)
-109.95%
3-year revenue growth (CAGR)
8.97%
3-year earnings per share growth (CAGR)
-9.77%
What the Analysts think about Certara
Analyst ratings (Buy, Hold, Sell) for Certara stock.
Bulls say / Bears say
Certara’s preliminary Q1 2025 revenue of $106 million beat analyst expectations of $104.4 million, and the board approved a $100 million share buyback, showing management’s confidence in cash generation and future growth. (Reuters)
Certara projects full-year 2025 revenue between $415 million and $425 million, topping the consensus forecast of $419.8 million and highlighting management’s optimism for continued demand in its biosimulation offerings. (Reuters)
Reuters names Certara as a top company using AI to model drug absorption, distribution, and toxicity, supporting the FDA’s efforts to cut animal testing and putting Certara at the forefront of modern drug development. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
Certara Financial Performance
Revenues and expenses
Certara Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Certara stock?
Certara (CERT) has a market cap of $1.8B as of September 18, 2025.
What is the P/E ratio for Certara stock?
The price to earnings (P/E) ratio for Certara (CERT) stock is 232 as of September 18, 2025.
Does Certara stock pay dividends?
No, Certara (CERT) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Certara dividend payment date?
Certara (CERT) stock does not pay dividends to its shareholders.
What is the beta indicator for Certara?
Certara (CERT) has a beta rating of 1.43. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.